In Reversal, Amgen Decides to Continue Offering 340B Pricing on Orphan Drugs

by Admin | July 31, 2014 11:52 am

July 31, 2014—In response to the Health Resources and Services Administration’s new 340B orphan drug exclusion interpretive rule, the biopharmaceutical manufacturer Amgen has decided to continue providing 340B pricing on its orphan-designated products to critical access hospitals, sole community hospitals, rural referral centers, and free-standing cancer hospitals. 

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1].    Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Endnotes:
  1. Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
  2. Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2014/07/in-reversal-amgen-decides-to-continue-offering-340b-pricing-on-orphan-drugs/

Copyright ©2024 340binformed.org unless otherwise noted.